Contineum Therapeutics, Inc (CTNM) insider trading
Every open-market stock purchase and sale by Contineum Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Carmine N. Stengone (CEO) sold $81.2K in the last 90 days.
- No open-market insider buys on record.
Last 12 months: insiders bought $0 (0 buys) and sold $1.9M (22 sales). Last close $8.35 on Oct 21, 2026.
Recent CTNM insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Sep 8, 2026 | Carmine N. Stengone (CEO) | Sold | $41.1K |
| Sep 8, 2026 | Carmine N. Stengone (CEO) | Bought (not open market) | $2.5K |
| Sep 8, 2026 | Carmine N. Stengone (CEO) | Bought (not open market) | — |
| Aug 3, 2026 | Carmine N. Stengone (CEO) | Sold | $40K |
| Aug 3, 2026 | Carmine N. Stengone (CEO) | Bought (not open market) | $2.5K |
| Aug 3, 2026 | Carmine N. Stengone (CEO) | Bought (not open market) | — |
| Jul 9, 2026 | Daniel S. Lorrain (C-suite exec) | Sold | $400 |
| Jul 9, 2026 | Daniel S. Lorrain (C-suite exec) | Bought (not open market) | $25 |
| Jul 9, 2026 | Daniel S. Lorrain (C-suite exec) | Bought (not open market) | — |
| Jul 8, 2026 | Carmine N. Stengone (CEO) | Sold | $40K |
| Jul 8, 2026 | Daniel S. Lorrain (C-suite exec) | Sold | $16.2K |
| Jul 8, 2026 | Carmine N. Stengone (CEO) | Bought (not open market) | $2.5K |
| Jul 8, 2026 | Daniel S. Lorrain (C-suite exec) | Bought (not open market) | $1K |
| Jul 8, 2026 | Daniel S. Lorrain (C-suite exec) | Bought (not open market) | — |
| Jul 8, 2026 | Carmine N. Stengone (CEO) | Bought (not open market) | — |
| Jul 1, 2026 | Daniel S. Lorrain (C-suite exec) | Sold | $91.7K |
| Jul 1, 2026 | Daniel S. Lorrain (C-suite exec) | Sold | $40.6K |
| Jul 1, 2026 | Daniel S. Lorrain (C-suite exec) | Bought (not open market) | $4.2K |
| Jul 1, 2026 | Daniel S. Lorrain (C-suite exec) | Bought (not open market) | — |
| Jun 30, 2026 | Daniel S. Lorrain (C-suite exec) | Sold | $462K |
| Jun 30, 2026 | Tim Watkins (C-suite exec) | Sold | $174K |
| Jun 30, 2026 | Carmine N. Stengone (CEO) | Sold | $160K |
| Jun 30, 2026 | Tim Watkins (C-suite exec) | Bought (not open market) | $48.7K |
| Jun 30, 2026 | Daniel S. Lorrain (C-suite exec) | Bought (not open market) | $29.1K |
| Jun 30, 2026 | Carmine N. Stengone (CEO) | Bought (not open market) | $7.6K |
Who's trading CTNM
- Carmine N. Stengone, CEO: sold $401K (7 sales), last Sep 8, 2026
- Daniel S. Lorrain, C-suite exec: sold $1.1M (19 sales), last Jul 9, 2026
- Tim Watkins, C-suite exec: sold $323K (5 sales), last Jun 30, 2026
- Lori Lyons-Williams, Director: other filings, last Jun 26, 2026
- Sarah Boyce, Director: other filings, last Jun 26, 2026
- Evert B. Schimmelpennink, Director: other filings, last Jun 26, 2026
- Gines Diego Miralles, Director: other filings, last Jun 26, 2026
- Todd R. Brady, Director: other filings, last Jun 26, 2026
- Troy A. Ignelzi, Director: other filings, last Jun 26, 2026
- Olivia C Ware, Director: other filings, last Jun 26, 2026
- John Stephen Healy, General Counsel: other filings, last Jan 30, 2026
- Peter T Slover, CFO: other filings, last Jan 30, 2026
Get free alerts when an insider at Contineum Therapeutics, Inc files a new trade →